TLR7 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL161530	1.00	20/20
SCHEMBL170115	1.00	20/20
SCHEMBL173521	1.00	20/20
SCHEMBL173576	1.00	20/20
SCHEMBL173879	1.00	20/20
SCHEMBL174281	1.00	20/20
SCHEMBL174300	1.00	20/20
SCHEMBL254747	1.00	20/20
SCHEMBL255040	1.00	20/20
SCHEMBL255072	1.00	20/20
SCHEMBL255136	1.00	20/20
SCHEMBL255327	1.00	20/20
SCHEMBL255388	1.00	20/20
Cpg-52852 (SCHEMBL483385)	1.00	20/20
SCHEMBL173264	0.98	20/20
SCHEMBL173990	0.84	20/20
SCHEMBL159189	0.82	20/20
SCHEMBL160369	0.82	20/20
SCHEMBL255046	0.78	20/20
SCHEMBL483645	0.76	20/20

Clinical trials — most relevant to TLR7 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Hydroxychloroquine Sulfate for Reduction of Proteinuria in Patients With IgA Nephropathy: a Self- Controlled Study	PHASE4	COMPLETED
Intradermal Influenza Vaccine in the Young	PHASE3	COMPLETED
Assessment the Activity Value of Isotretinoin (13- Cis-Retinoic Acid ) in the Treatment of COVID-19 ( Isotretinoin in Treatment of COVID-19) (Randomized)	PHASE3	UNKNOWN
Efficacy of Ibuprofen Chronotherapy in Healing After Surgical Extraction of the Mandibular Third Molar	PHASE2/PHASE3	UNKNOWN
BDB001-201: A Clinical Study of BDB001 in Patients With PD-(L)1 Refractory Solid Tumors	PHASE2	COMPLETED
In Situ Vaccine for Low-Grade Lymphoma: Combination of Intratumoral Flt3L and Poly-ICLC With Low-Dose Radiotherapy	PHASE1/PHASE2	COMPLETED
Single-step Antigen Loading and TLR Activation of Dendritic Cells in Melanoma Patients	PHASE1/PHASE2	COMPLETED
A Study of Hydroxychloroquine Sulfate for Reduction of Proteinuria in Patients With IgA Nephropathy	PHASE2	COMPLETED
Toll-like Receptor (TLR) Ligand Matured Dendritic Cell Vaccination in Melanoma Patients	PHASE1/PHASE2	COMPLETED
Efficacy and Safety of Drug Combination Therapy of Isotretinoin and Some Antifungal Drugs as A Potential Aerosol Therapy for COVID-19 : An Innovative Therapeutic Approach COVID-19	PHASE2	UNKNOWN
Imiquimod for Breast Cancer Patients With Chest Wall Recurrence or Skin Metastases	PHASE2	COMPLETED
Polyinosinic-Polycytidylic Acid-poly-L-lysine Carboxymethylcellulose (Poly-ICLC) in Healthy Volunteers	PHASE1	COMPLETED
An Investigation of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2245035 in Healthy Volunteers and Allergic Rhinitics.	PHASE1	COMPLETED
RBL001/RBL002 Phase I Clinical Trial	PHASE1	COMPLETED
The Effects of GLA on Human Volunteers	PHASE1	COMPLETED
Clinical Study of BDB018: Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors	PHASE1	COMPLETED
A Multipeptide Vaccine Plus Toll-Like Receptor Agonists in Melanoma Patients	PHASE1	COMPLETED
Dendritic Cell Vaccine With Imiquimod for Patients With Malignant Glioma	PHASE1	COMPLETED
Neoadjuvant Imiquimod Immunotherapy for Oral Cancer	EARLY_PHASE1	COMPLETED
Impact of Nasal Saline Irrigations on Viral Load in Patients With COVID-19	nan	COMPLETED
Bacteremia in Intensive Care Unit (ICU)	nan	UNKNOWN
Toll-like Receptor 2 Gene Polymorphism, Serum Cytokines and Susceptibility to Disease Severity or Treatment Response of Pulmonary Tuberculosis	nan	COMPLETED
Th1/Th2/Th17/TREG and TLRs Activation/KIR for COVID 19 Prediction of Outcome	nan	COMPLETED
Biomarkers of Trained Immunity Following MMR Vaccination	nan	COMPLETED
Expression of Toll-like Receptors 3 , 7 and 9 in Peripheral Blood Mononuclear Cells of COVID-19 Patients	nan	UNKNOWN
X-linked Biological Response to HIV Sensing: the ANRS EP 53 Study	nan	COMPLETED
Deep Phenotyping of Cutaneous Lupus Erythematosus	nan	UNKNOWN
Differences in Immune Response Among HIV-1-infected Individuals With Previous or Current COVID-19 (CoVIHDis).	nan	UNKNOWN
TLR4 Polymorphisms and Risk of Skin Cancer	nan	COMPLETED
Neuro-Immune Interactions in the Gut	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a TLR7 binder may also engage these)

Protein	Name	Similarity
P58681	—	0.998	P58681 →
Q6T752	—	0.987	Q6T752 →
Q689D1	—	0.987	Q689D1 →
Q95M53	—	0.987	Q95M53 →
B5T267	—	0.986	B5T267 →
Q2PZH4	—	0.985	Q2PZH4 →
B3Y618	—	0.985	B3Y618 →
B2LT61	—	0.984	B2LT61 →
Q9EPQ1	—	0.984	Q9EPQ1 →
Q0ZUL9	—	0.983	Q0ZUL9 →
B2LT64	—	0.983	B2LT64 →
TLR2	Toll-like receptor 2	0.983	landscape →
Q95LA9	—	0.983	Q95LA9 →
B3Y615	—	0.983	B3Y615 →
B3Y613	—	0.982	B3Y613 →
Q0GC71	—	0.982	Q0GC71 →
Q2V897	—	0.982	Q2V897 →
B3Y614	—	0.982	B3Y614 →
B2LT62	—	0.980	B2LT62 →
Q9EPW9	—	0.980	Q9EPW9 →
Q9R1F8	—	0.979	Q9R1F8 →
Q9DD78	—	0.978	Q9DD78 →
B2LT65	—	0.978	B2LT65 →
Q9QUN7	—	0.978	Q9QUN7 →
Q9BXR5	—	0.976	Q9BXR5 →
TLR1	Toll-like receptor 1	0.975	landscape →
P58682	—	0.973	P58682 →
Q6GV17	—	0.973	Q6GV17 →
TLR8	Toll-like receptor 8	0.972	landscape →
A0N0X6	—	0.971	A0N0X6 →